Trials / Completed
CompletedNCT00603993
Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
A Non-Randomized, Open-Label, Roll-Over Study With Self Injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab | 40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-11-01
- First posted
- 2008-01-29
- Last updated
- 2011-06-21
- Results posted
- 2010-02-04
Locations
16 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00603993. Inclusion in this directory is not an endorsement.